Ampio Pharmaceuticals, Inc. said the FDA has accepted its IND for Optina, an oral drug used in the treatment of diabetic macular edema, or DME. Optina had been given 505-b-2 status by FDA in July, 2012. Drugs designated under this pathway can be approved on a single trial. DME is a devastating complication of diabetes and is manifested by local and systemic inflammation. Optina also has the potential to treat other systemic complications of diabetes such as nephropathy, said the company.